Factors Associated with Parathyroid Hormone Control in Haemodialysis Patients with Secondary Hyperparathyroidism Treated with Cinacalcet in Real-world Clinical Practice: Mimosa Study

Overview

Journal Clin Kidney J

Publisher Oxford University Press

Specialty Nephrology

Date 2019 Dec 7

PMID 31807302

Citations 12

Authors

Jacques Rottembourg

Pablo Urena-Torres

Daniel Toledano

Victor Gueutin

Abdelaziz Hamani

Olivier Coldefy

Hedia Hebibi

Thomas Guincestre

Corinne Emery

Affiliations

Soon will be listed here.

Abstract

Background: Secondary hyperparathyroidism (SHPT) is frequent in haemodialysis (HD) patients. Oral cinacalcet-hydrochloride (HCl) decreases parathyroid hormone (PTH); however, real-life PTH data, according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, are still lacking. Our goal is to assess the percentage of cinacalcet-HCl-treated HD patients with controlled SHPT (PTH <9× upper limit of the normal range) after 12 months (M12) of treatment.

Methods: This is a retrospective observational study in HD patients with SHPT treated by cinacalcet-HCl between 2005 and 2015 and dialysed in seven French HD centres using the same database (Hemodial™).

Results: The study included 1268 patients with a mean (standard deviation) follow-up of 21 ± 12 months. Their mean dialysis vintage was 4.3 ± 5.6 years. PTH values were available and exploitable at M12 in 50% of them (645 patients). Among these patients, 58.9% had controlled (mean PTH of 304 ± 158 pg/mL) and 41.1% uncontrolled SHPT (mean PTH of 1084 ± 543) at M12. At the baseline, patients with controlled SHPT were older (66 ± 15 versus 61 ± 17 years), and had lower PTH (831 ± 346 versus 1057 ± 480 pg/mL) and calcaemia (2.18 ± 0.2 versus 2.22 ± 0.19 mmol/L) than uncontrolled patients. In multivariate analysis, these three factors still remained significantly associated with controlled SHPT.

Conclusion: In this real-life study, 41.1% of HD patients with SHPT treated with cinacalcet-HCl remained with a PTH above the KDIGO recommended target after 12 months of treatment. Apart from the possibility of non-compliance, the severity of SHPT appears to be a major factor determining the response to cinacalcet-HCl treatment, reinforcing the importance of treating SHPT at earlier stages.

Citing Articles

Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis.

Liu X, Liu Y, Zheng P, Xie X, Li Z, Yang R Eur J Clin Pharmacol. 2024; 80(10):1555-1569.

PMID: 39002024 DOI: 10.1007/s00228-024-03730-5.

Parathyroidectomy: still the best choice for the management of severe secondary hyperparathyroidism.

Ramos L, Via Reque Cortes D, Dos Reis L, Montenegro F, Arap S, Brescia M J Bras Nefrol. 2023; 46(2):e20230024.

PMID: 38039492 PMC: 11210536. DOI: 10.1590/2175-8239-JBN-2023-0024en.

Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review.

Li X, Ding W, Zhang H Front Endocrinol (Lausanne). 2023; 14:1146955.

PMID: 37538795 PMC: 10395090. DOI: 10.3389/fendo.2023.1146955.

Clinical Characteristics and Management of Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: A Feasibility Analysis of Electronic Health Records Using Natural Language Processing.

Ortiz A, Portoles J, Pino-Pino M, Barea J, Lopez M, de Sequera P Kidney Dis (Basel). 2023; 9(3):187-196.

PMID: 37497203 PMC: 10368074. DOI: 10.1159/000528784.

Biochemical spectrum of parathyroid hormone disorders in patients attending Tribhuvan University Teaching Hospital, Kathmandu, Nepal.

Niraula A, Baidya S, Sharma V, Tuladhar E, Dubey R, Bhattarai A SAGE Open Med. 2023; 11:20503121231182204.

PMID: 37342614 PMC: 10278423. DOI: 10.1177/20503121231182204.

References

Martin de Francisco A, Gillespie I, Gioni I, Floege J, Kronenberg F, Marcelli D . Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia. 2015; 36(2):164-75. DOI: 10.1016/j.nefro.2015.10.006. View

Urena-Torres P, Bridges I, Christiano C, Cournoyer S, Cooper K, Farouk M . Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant. 2013; 28(5):1241-54. DOI: 10.1093/ndt/gfs568. View

Burnier M, Pruijm M, Wuerzner G, Santschi V . Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant. 2014; 30(1):39-44. DOI: 10.1093/ndt/gfu015. View

Block G, Bushinsky D, Cunningham J, Drueke T, Ketteler M, Kewalramani R . Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017; 317(2):146-155. DOI: 10.1001/jama.2016.19456. View

Ketteler M, Martin K, Cozzolino M, Goldsmith D, Sharma A, Khan S . Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant. 2011; 27(5):1942-9. PMC: 3339443. DOI: 10.1093/ndt/gfr531. View

Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B . The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008; 3(1):36-45. PMC: 2390975. DOI: 10.2215/CJN.03591006. View

Chertow G, Parfrey P . Cinacalcet for cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2013; 368(19):1844-5. DOI: 10.1056/NEJMc1301247. View

Urena P, Fouque D, Brunet P, Touam M, Reglier J . [Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice - the ECHO observational study: French experience]. Nephrol Ther. 2012; 8(7):527-33. DOI: 10.1016/j.nephro.2012.05.002. View

Saran R, Bragg-Gresham J, Rayner H, Goodkin D, Keen M, van Dijk P . Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 2003; 64(1):254-62. DOI: 10.1046/j.1523-1755.2003.00064.x. View

10.

Lassalle M, Ayav C, Frimat L, Jacquelinet C, Couchoud C . The essential of 2012 results from the French Renal Epidemiology and Information Network (REIN) ESRD registry. Nephrol Ther. 2014; 11(2):78-87. DOI: 10.1016/j.nephro.2014.08.002. View

11.

Arnold A, Brown M, Urena P, Gaz R, Sarfati E, Drueke T . Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995; 95(5):2047-53. PMC: 295791. DOI: 10.1172/JCI117890. View

12.

Cozzolino M, Urena-Torres P, Vervloet M, Brandenburg V, Bover J, Goldsmith D . Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. Nephrol Dial Transplant. 2014; 29(10):1815-20. DOI: 10.1093/ndt/gft514. View

13.

Browne T, Merighi J . Barriers to adult hemodialysis patients' self-management of oral medications. Am J Kidney Dis. 2010; 56(3):547-57. DOI: 10.1053/j.ajkd.2010.03.002. View

14.

Urena Torres P, Prie D, Beck L, Friedlander G . New therapies for uremic secondary hyperparathyroidism. J Ren Nutr. 2006; 16(2):87-99. DOI: 10.1053/j.jrn.2006.01.011. View

15.

Schmid H, Hartmann B, Schiffl H . Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009; 14(5):185-90. PMC: 3351975. DOI: 10.1186/2047-783x-14-5-185. View

16.

Baena M, Faus M, Fajardo P, Luque F, Sierra F, Martinez-Olmos J . Medicine-related problems resulting in emergency department visits. Eur J Clin Pharmacol. 2006; 62(5):387-93. DOI: 10.1007/s00228-006-0116-0. View

17.

Fishbane S, Shapiro W, Corry D, Vicks S, Roppolo M, Rappaport K . Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008; 3(6):1718-25. PMC: 2572296. DOI: 10.2215/CJN.01040308. View

18.

Raggi P, Chertow G, Urena Torres P, Csiky B, Naso A, Nossuli K . The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2010; 26(4):1327-39. DOI: 10.1093/ndt/gfq725. View

19.

Wetmore J, Gurevich K, Sprague S, da Roza G, Buerkert J, Reiner M . A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015; 10(6):1031-40. PMC: 4455208. DOI: 10.2215/CJN.07050714. View

20.

Hirai T, Nakashima A, Takasugi N, Yorioka N . Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial. 2010; 14(6):577-82. DOI: 10.1111/j.1744-9987.2010.00843.x. View